Consumer Reports: Pharmacies Don’t Always Provide Required Drug Warnings

If you, a friend or loved one take any prescription medication, a new study might be of interest. The findings are rather discomforting, to say the least.

Many people who take prescription medications rely on the drug labels and package inserts for important instructions and warnings. But a new article from Consumer Reports reveals some frightening results about adults misunderstanding prescription drug labels.

Consumer Reports staff members recently picked up prescriptions from five national pharmacy chain stores, and they found bottle labels and patient information sheets that were both difficult to read and lacking in information.

The magazine states that approximately 90 million adults in the United States misunderstand at least some of the instructions on prescription drug labels, according to the Institute of Medicine. And the Food and Drug Administration has found that only 75 percent of the leaflets included with prescriptions meet the agency’s minimum recommended criteria for usefulness. Small print, technical language and incomplete instructions might play a role in the roughly 500,000 preventable outpatient medication errors that occur nationally each year.

Consumer Reports’ staff members filled prescriptions for five  milligrams of warfarin, a common generic blood thinner, at Costco, CVS, Target, Walgreens and Wal-Mart stores near their offices in Yonkers, N.Y. Although the findings are not nationally representative for each chain,  Consumer Reports says they do provide a glimpse into common issues consumers may face.

Warfarin is the second-most-likely prescription drug to cause serious adverse reactions leading to emergency room visits, so the Consumer Reports staffers expected fairly clear and moderately consistent warnings and instructions among all five prescriptions. Instead, they found that critical information was confusing, misleading, buried or absent.

Consumer Reports’ staff members found that most bottle labels were fairly easy to read, but the typeface on the Costco label was smaller than experts advise. And Costco, Walgreens and Wal-Mart did not list the common brand name, Coumadin, in addition to the generic name, warfarin.

The Target bottle clearly listed four warnings about warfarin, according to Consumer Reports. The Walgreens bottle also had four, CVS’s listed three, Costco’s mentioned two and Wal-Mart’s, surprisingly, had none. Bottles from two later visits to Wal-Mart had three warnings each.

As for the patient information sheets, CR reported that only Costco provided the FDA-approved medication guide that is required for some drugs, including warfarin. CVS and Target representatives said that their pharmacies automatically printed medication guides for patients. But they weren’t included in the prescriptions that were received. Walgreens and Wal-Mart didn’t respond to Consumer Reports’ queries.

Consumer Reports says all five pharmacies did provide their own patient information materials containing drug information, but they differed from the federally mandated, FDA-approved medication guide, which should have been included in the packages.

One difference involved warfarin’s possible side effects, which, according to the official FDA guide, include life-threatening bleeding problems; skin-tissue damage; “purple-toes syndrome,” which can lead to amputation; allergic reactions; liver problems; low blood pressure; swelling; low red blood cell counts; paleness; fever; and rashes. But the inserts from Walgreens, Wal-Mart and Target reported under the heading “possible side effects” that there are “no common side effects with the proper use of this medicine.” Those inserts instead included a list of serious symptoms and “unusual effects” — shortness of breath and bloody stool or urine among them — and followed up with a caveat referring patients to their doctor for information about other possible side effects.

According to Consumer Reports, none of the pharmacy-provided inserts listed additional side effects that can be caused by warfarin, such as gas, tiredness, hair loss, change in the way things taste, and chills.

The magazine say all the patient information materials did include the drug’s “black box” safety warning that mentioned “severe and sometimes fatal bleeding” and other cautions. And all had information on how food, supplements and drugs can cause interactions. While all that was helpful, information in the inserts from Costco, CVS, Target and Walgreens was in a tiny typeface, and Walgreens’ insert had tight spacing between lines, making it difficult to read. Wal-Mart’s insert had larger lettering and was spread over four pages. And none seemed to be written in plain English.

Consumer Reports says the bottom line is: Don’t rely solely on labels and inserts for information about the medication you take; talk with your doctor and pharmacist.

We at John Bales Attorneys agree wholeheartedly.

Posted in Legal News | Tagged , , , , | Leave a comment

Hip Implant Complaints Surge

Have you or a loved one had a hip replacement that is causing pain or problems?

 If so, we at John Bales Attorneys would like to hear from you.  Our contact information is at the end of this very important article that was published in the New York Times.

The federal government has received a surge in complaints in recent months about failed hip replacements, suggesting that serious problems persist with some types of artificial hips even as researchers scramble to evaluate the health dangers.

An analysis of federal data by The New York Times indicates that the Food and Drug Administration has received more than 5,000 reports since January about several widely used devices known as metal-on-metal hips, more than the agency had received about those devices in the previous four years combined.

The vast majority of filings appear to reflect patients who have had an all-metal hip removed, or will soon undergo such a procedure because a device failed after only a few years; typically, replacement hips last 15 years or more.

The mounting complaints confirm what many experts have feared — that all-metal replacement hips are on a trajectory to become the biggest and most costly medical implant problem since Medtronic recalled a widely used heart device component in 2007. About 7,700 complaints have been filed in connection with that recall.

Though immediate problems with the hip implants are not life-threatening, some patients have suffered crippling injuries caused by tiny particles of cobalt and chromium that the metal devices shed as they wear.

Hip replacement is one of the most common procedures in the United States and, until a recent sharp decline, all-metal implants — one in which both the artificial ball and cup are made of metal — accounted for nearly one-third of the estimated 250,000 replacements performed each year. According to one estimate, some 500,000 patients have received an all-metal replacement hip.

One of the most problematic devices, the A.S.R., or Articular Surface Replacement, was recalled last year by Johnson & Johnson and accounted for 75 percent of the complaints reviewed by The Times. A precise count of failed implants reported to the F.D.A. is hard to come by because of the agency’s overlapping reporting system, though The Times sought to eliminate duplicate reports about the same incident. Some complaints came from outside the United States.

Under F.D.A. rules, many all-metal devices were sold without testing in patients or without a requirement that producers track their performance. But in an unusual intervention, the F.D.A. in May ordered producers to study how frequently the devices were failing and to examine the threat to patients. Now, researchers say, producers face substantial hurdles in recruiting the hundreds of patients needed to conduct sound studies because of the lack of patient registries.

“They are grasping at how they are going to get this information,” said Dr. Robert S. Namba, an orthopedic surgeon with Kaiser Permanente.

In addition, researchers are struggling to understand the tissue damage caused by the metallic debris. While some patients experience pain, other patients with the same damage have no pain, complicating decisions about whether to remove devices.

As problems and questions grow, most surgeons are abandoning the all-metal hips, saying they are unwilling to expose new patients to potential dangers when safer alternatives — mainly replacements that combine metal and plastic components — are available. Some researchers also fear that many all-metal hips suffer from a generic flaw. Current use of all metal devices has plummeted to about 5 percent of the market, though a few of the models are performing relatively well in select patients.

“It is like playing Russian roulette,” said Dr. Geoffrey H. Westrich, an orthopedic surgeon at the Hospital for Special Surgery in New York, who has stopped using all-metal implants.

Dr. William Maisel, the chief scientist of the F.D.A. division that oversees medical devices, said he believed that producers would mount rigorous studies and find answers. But he acknowledged that it could take several years.

“There is not an existing infrastructure for studying this kind of information,” Dr. Maisel said.

For many patients, it is too late. In 2008, Ann Morrison, a physical therapist from Newark, Del., received all-metal replacements for both of her hips. But Ms. Morrison, 50, soon experienced pain, rashes and inflammation.

Last year, the devices were replaced, but by then, she said, debris-caused tissue damage was so extensive that she now needs a brace to walk and still cannot work. She called the F.D.A.’s order for medical studies a “joke.”

“We will be the little crash test dummies here until they figure out the health ramifications for us down the road,” said Ms. Morrison, who has sued the DePuy division of Johnson & Johnson, which made her implants.

To conduct its analysis, The Times reviewed complaints filed with the F.D.A. from 2007 through this June for several implants, including the A.S.R. and the Durom cup, a component sold by Zimmer Holdings.

Typically, the number of complaints filed with the F.D.A. about a product understates a problem because while companies must file reports, doctors and patients do not have to. The filing volume for the A.S.R. and the Durom cup probably reflects a surge of lawsuits filed against their makers.

The Times review found some 7,500 complaints about the A.S.R., nearly 5,000 of them coming since January. In the case of the Durom cup, about 1,600 complaints were filed with the regulator from 2007 to this June.

Because complaints to the F.D.A. are not uniform, it is impossible to say how many adverse reports about all-metal hips have been submitted. For example, the Times analysis found some 200 complaints about an all-metal version of another DePuy device called the Pinnacle as well as 400 additional complaints that noted metal-related problems in Pinnacle patients. But the Pinnacle is sold in several versions, so it was not clear how many of the metal-related complaints were linked to the all-metal device.

A spokesman for Zimmer Holdings said the Times review was “in the ballpark” of the company’s assessment of the drug administration’s filings. A DePuy spokeswoman declined to disclose the number of A.S.R. complaints that the company forwarded to the F.D.A. She maintained that the Pinnacle was performing well.

DePuy, Zimmer and another producer of metal hips, Wright Medical, declined to discuss the study proposals they had submitted to the F.D.A. to comply with its May order. A fourth company, Biomet, said it had proposed mounting a study of 400 patients who received its devices that would draw in part on studies already under way. The F.D.A. declined to release producers’ proposals, saying that they contained “confidential commercial information.” The agency has until November to decide on the plans’ adequacy.

In an effort to recruit patients, companies have recently contacted, researchers said, health systems like Kaiser Permanente and hospitals that operate their own implant registries.

Meanwhile, researchers say it may be a year before standard protocols are formulated that may be central to the future studies, like a uniform procedure to measure metallic ions in a patient’s blood or how to calibrate diagnostic equipment to best detect tissue damage.

If you or a loved one had a hip replacement that is causing pain or problems, contact the experienced, professional lawyers at John Bales Attorneys.  Complete a FREE Online Consultation Form or call us toll free 1-800-CALL JOHN (1-800-225-5564) 24 hours, 7 days a week.

 
Posted in Legal Connection | Tagged , , , , , | Leave a comment

FDA Issues Public Health Notification Regarding Surgical Mesh

The following public health notification is from the United States Food and Drug Administration’s web site. We at John Bales Attorneys think it is important information.
Over the past three years, FDA has received over 1,000 reports from nine surgical mesh manufacturers of complications that were associated with surgical mesh devices used to repair POP and SUI. These mesh devices are usually placed transvaginally utilizing tools for minimally invasive placement.
The most frequent complications included erosion through vaginal epithelium, infection, pain, urinary problems, and recurrence of prolapse and/or incontinence. There were also reports of bowel, bladder, and blood vessel perforation during insertion. In some cases, vaginal scarring and mesh erosion led to a significant decrease in patient quality of life due to discomfort and pain, including dyspareunia.
Treatment of the various types of complications included additional surgical procedures (some of them to remove the mesh), IV therapy, blood transfusions, and drainage of hematomas or abscesses.
Specific characteristics of patients at increased risk for complications have not been determined. Contributing factors may include the overall health of the patient, the mesh material, the size and shape of the mesh, the surgical technique used, concomitant procedures undertaken (e.g. hysterectomy), and possibly estrogen status.

To speak with a Florida injury attorney who is dedicated to pursuing your rights, complete a FREE Online Consultation Form, or call us toll free at 1-800-CALL JOHN (1-800-225-5564) 24 hours a day, 7 days a week.

Posted in Legal Connection | Leave a comment

FDA Issues Notification on Antifungal Drug

The U.S Food and Drug Administration has issued a notification that we at John Bales Attorneys think the public should be aware of.
The FDA says that the antifungal drug Diflucan (its generic name is fluconazole), taken in chronic, high doses of 400-800 milligrams a day may be associated with a rare and distinct set of birth defects in infants whose mothers were treated with the drug during the first trimester of pregnancy.
The agency says this risk does not appear to be associated with a single, low dose (150 mg) of the drug that is prescribed to treat vaginal yeast infection.
There are several published case reports of birth defects in infants whose mothers were treated with high doses of fluconazole (400-800 mg/day) for serious and life-threatening fungal infections during most or all of the first trimester.
The FDA says Healthcare professionals should be aware of the potential risks with long-term, high-dose use of fluconazole and counsel patients if the drug is used during pregnancy, or if a patient becomes pregnant while taking the drug.

If you or a loved one have taken fluconazole, contact a John Bales Florida drug injury attorney today. Complete a FREE Online Consultation Form or call us toll free 1-800-CALL JOHN (1-800-225-5564) 24 hours, 7 days a week.

Posted in Legal Information | Tagged , , , , , | Leave a comment

What the Jury Never Sees

Posted in Legal Information, TV Segments | Leave a comment

Insurance Bill SB408

Posted in Legal Information, TV Segments | Tagged , , , , | Leave a comment

Mild Traumatic Brain Injury Linked to Dementia in Veterans

New reports discussed at the Alzheimer’s Association’s International Conference state that older veterans who have sustained a mild brain injury were likely to develop Alzheimer’s disease and other dementia-related diseases later in life. The study also found a high rate of mild cognitive impairment, or “pre-Alzheimer’s,” in retired pro-football players who suffered from multiple concussions during their careers.

According to the U.S. Department of Health and Human Services, the term “mild traumatic brain injury” (MTBI) is used interchangeably with the term “concussion”. An MTBI or concussion is defined as a complex pathophysiologic process affecting the brain, induced by traumatic biomechanical forces secondary to direct or indirect forces to the head.

MTBI is caused by a blow or jolt to the head that disrupts the function of the brain. This disturbance of brain function is typically associated with normal structural neuroimaging findings.

The study’s findings negate older reports which stated that only moderate or severe brain injuries led to dementia. The study raises concerns for current service men and women who have suffered from explosions in recent years.

The veterans study was led by Dr. Kristine Yaffe, a University of California professor and director of the Memory Disorders Clinic at the San Francisco VA Medical Center. “It’s by far the largest” study of brain injury and dementia risk, she said. “It’s never been looked at in veterans specifically. It’s not just one kind of TBI or super-severe TBI” that poses a danger, Yaffe said.

The study included 281,540 veterans who received care from Veterans Health Administration hospitals from 1997 to 2000 and had at least one follow-up visit from 2001-2007. The participants were 55 years of age or older, and no one had been diagnosed with dementia when the study began. Records showed that 4,902 of the veterans had suffered a traumatic brain injury, or TBI, ranging from concussions to skull fractures.

Over the next seven years, more than 15 percent of those who had suffered a brain injury were diagnosed with dementia versus only 7 percent of the others – a more than doubled risk. Worse still, severity of the injury made no difference in the odds of developing dementia.

Posted in Legal Information | Tagged , , | Leave a comment

Topamax

Posted in Legal Information, TV Segments | Leave a comment

Asbestos Dangers

Posted in TV Segments | Tagged , , , | Leave a comment

Insurance Disputes

Posted in TV Segments | Leave a comment